Dyax Announces Final Patient Treated in Second Phase 3 Clinical Trial (EDEMA4) of DX-88 in Hereditary Angioedema
Company's Clinical Research Provider, BattelleCRO, to Shut Down
26-Jun-2008 -
Dyax Corp. announced that it has treated the final patient in its second Phase 3, 96-patient trial of DX-88, known as EDEMA4, for the treatment of acute attacks of hereditary angioedema (HAE). HAE is a rare and life-threatening inflammatory condition for which there is no approved therapy in the ...
biologics
clinical trials
Dyax
+2